Clinical trials: Time in Range
Type 1 Diabetes
Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes
The main objective is to determine the efficacy of Lyumjev (insulin) in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1.
- Trial name
- FAST 1 (NCT05508061)
- Testing
- Insulin Lispro Cartridge [Lyumjev], Insulin Lispro Cartridge
- Where
- 3 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Inreda Diabetic B.V.
Diabetes Mellitus, Diabetes Mellitus ( Type 1 and Type 2)
PMCF Study of GX-01S CGM in Adults With Diabetes
This clinical study evaluates the GX-01S Continuous Glucose Monitoring (CGM) System in adults with Type 1 or Type 2 diabetes. CGM systems measure glucose levels continuously throughout the day, providing real-time information…
- Trial name
- PROMISE-GX (NCT07802327)
- Testing
- GX-01S Continuous Glucose Monitoring System
- Volunteers
- 100 people
- Sponsor
- MicroTech Medical（Hangzhou）Co.,Ltd.
Type 2 Diabetes
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.
- Trial name
- NCT04605991
- Testing
- LY900014, Insulin Glargine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
- Trial name
- NCT04585776
- Testing
- LY900014, Insulin Degludec
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus (T1DM)
The Effect of Hedia Diabetes Assistant on TiMe-in-range in People With Type 1 Diabetes and Sub-Optimal Glycemic Control in France - A Randomised Controlled Trial.
The goal of this randomized controlled study is to assess the clinical performance and safety of Hedia Diabetes Assistant in adults with type 1 diabetes and suboptimal glycemic control in France.
- Trial name
- TEMPO (NCT06819306)
- Testing
- Hedia Diabetes Assistant
- Where
- 6 sites in France
- Volunteers
- 154 people
- Sponsor
- Hedia ApS
Diabetes Mellitus, Type 1
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
Amidst medical innovations, many Type 1 diabetes patients using advanced therapy show improved control but still suffer from diabetes-related distress.
- Trial name
- PRO-DIAB-1 (NCT06050642)
- Testing
- enhanced care model provided by Timkl, a home support provider
- Where
- France
- Volunteers
- 340 people
- Sponsor
- timkl
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Treated With Insulin
A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections
The purpose of this study is to collect CGM, A1c and Quality of Life data in subjects with Type 2 diabetes before and after transitioning from Multiple Daily Injections to Basal plus Bolus with Afrezza® inhaled insulin.
- Trial name
- NCT04125082
- Testing
- Afrezza Inhalant Product
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Diabetes and Glandular Disease Clinic
Type 2 Diabetes Mellitus
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
The purpose of the study was to demonstrate if iGlarLixi (Soliqua 100/33) would improve glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes…
- Trial name
- Soli-CGM (NCT05114590)
- Testing
- Insulin glargine/Lixisenatide
- Where
- 18 sites in United States
- Volunteers
- 124 people
- Sponsor
- Sanofi
Pain
TENS and Heat for Reducing Back Pain in Humans
Lower back pain is one of the most common and most expensive impairments costing time and expense in the work force today. With the effects on cognitive skills and addictive side effects of opioids and other prescription pain…
- Trial name
- NCT03740750
- Testing
- Thermacare heat wraps, TENS
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Future Sciene Technology
Atrial Fibrillation, Deep Vein Thrombosis
Association Between Genetic Variant Scores and Warfarin Effect
Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Intracardiac Thrombus, Pulmonary Embolism
- Trial name
- AWARE1 (NCT03894878)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cipherome, Inc.
Diabete Mellitus, Type2diabetes
CGM Experience, Preferences & Blood Glucose Parameters
This is an open-label, prospective, multicenter observational study designed to evaluate the perceived benefits, device experience, preference, and glucose-related parameters associated with the Instara-1 Continuous Glucose…
- Conditions
- Diabete Mellitus, Type2diabetes, type1diabetes, Gestational Diabetes
- Trial name
- NCT07607015
- Testing
- CGM
- Volunteers
- 75 people
- Sponsor
- Getz Pharma
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Type 1 Diabetes
Hybrid Closed Loop System for Patients on Multiple Daily Insulin Injections
The objective of this study is to assess structured group education onboarding protocol of the 670 G Hybrid Closed Loop (HCL) systems in achieving glucose control of patients on Multiple Daily Insulin Injections (MDI).
- Trial name
- NCT04145804
- Testing
- Medtronic Minimed 670G insulin pump
- Where
- Qatar
- Volunteers
- 40 people
- Sponsor
- Hamad Medical Corporation